Nationwide cohort for renal cell carcinoma data collection
PROspective Renal Cancer Cohort (PRO-RCC)
This study is collecting real-life health information from people with kidney cancer in the Netherlands to help improve treatments and understand their experiences better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | PROspective Renal Cancer Cohort Foundation Academic / other |
| Locations | 27 sites (Amsterdam, North Holland and 26 other locations) |
| Trial ID | NCT05326620 on ClinicalTrials.gov |
What this trial studies
PRO-RCC is a multicenter cohort study aimed at collecting real-world clinical data and patient-reported outcomes for patients with localized or metastatic renal cell carcinoma in the Netherlands. The study integrates clinical data collection with the Netherlands Cancer Registry and includes patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs). Participants can also consent to be part of 'Trial within cohorts' (TwiC) studies, allowing for randomized interventional research within the cohort framework. This infrastructure supports both observational and interventional studies to improve understanding and treatment of renal cell carcinoma.
Who should consider this trial
Good fit: Ideal candidates for this study are newly diagnosed patients with renal cell carcinoma or synchronous metastatic renal cell carcinoma, aged over 18 and capable of understanding Dutch.
Not a fit: Patients who do not meet the inclusion criteria, such as those under 18 or unable to understand Dutch, will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of renal cell carcinoma and improve patient care through better data on treatment outcomes and patient experiences.
How similar studies have performed: Other studies utilizing similar cohort designs have shown promise in improving patient outcomes and understanding disease progression, indicating that this approach is both tested and potentially effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * newly diagnosed patients with RCC or synchronous metastatic RCC * metachronous metastasized RCC * age \>18 years * capable of understanding Dutch language Exclusion Criteria: * n/a
Where this trial is running
Amsterdam, North Holland and 26 other locations
- Amsterdam UMC locatie VUMC — Amsterdam, North Holland, Netherlands (Recruiting)
- Jeroen Bosch Ziekenhuis — 's-Hertogenbosch, Netherlands (Recruiting)
- Jeroen Bosch Ziekenhuis — 's-Hertogenbosch, Netherlands (Recruiting)
- Meander Medisch Centrum — Amersfoort, Netherlands (Recruiting)
- Gelre ziekenhuis — Apeldoorn, Netherlands (Recruiting)
- Rijnstate — Arnhem, Netherlands (Recruiting)
- Amphia Ziekenhuis — Breda, Netherlands (Recruiting)
- Deventer Ziekenhuis — Deventer, Netherlands (Recruiting)
- Albert Schweitzer — Dordrecht, Netherlands (Recruiting)
- Catharina ziekenhuis — Eindhoven, Netherlands (Recruiting)
- Maxima MC — Eindhoven, Netherlands (Recruiting)
- Treant — Emmen, Netherlands (Recruiting)
- Umcg — Groningen, Netherlands (Recruiting)
- Spaarne Gasthuis — Haarlem, Netherlands (Recruiting)
- Tergooi MC — Hilversum, Netherlands (Recruiting)
- Medisch Centrum Leeuwarden — Leeuwarden, Netherlands (Recruiting)
- Maastricht UMC — Maastricht, Netherlands (Recruiting)
- St Antonius Ziekenhuis — Nieuwegein, Netherlands (Recruiting)
- Canisius Wilhelmina Ziekenhuis — Nijmegen, Netherlands (Recruiting)
- Bravis ziekenhuis — Roosendaal, Netherlands (Recruiting)
- Erasmus MC — Rotterdam, Netherlands (Recruiting)
- Maasstad ziekenhuis — Rotterdam, Netherlands (Recruiting)
- St. Franciscus ziekenhuis — Rotterdam, Netherlands (Recruiting)
- Haaglanden Medisch Centrum — The Hague, Netherlands (Recruiting)
- UMC Utrecht — Utrecht, Netherlands (Recruiting)
- Viecuri — Venray, Netherlands (Recruiting)
- Isala — Zwolle, Netherlands (Recruiting)
Study contacts
- Principal investigator: Adriaan Bins, MD, PhD — Amsterdam UMC
- Study coordinator: Hilin Yildirim, MD
- Email: h.yildirim@iknl.nl
- Phone: 0031643202583
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.